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1Introduction
Lung cancer is the first most common cancer among men 
and the third most common cancer among women world-
wide with 1.82 million cases and 1.59 million deaths due 
to lung cancer in 2012 [1]. The incidence rate has decreased 
since the mid- 1980s by 1.9% in men and the mid- 2000s 
by 1.2% in women. The mortality rate declined from 
2004 and 2008 by 2.6% and 0.9% per year in men and 
women, respectively [2]. Tobacco smoking accounts for 
more than 80% of all lung cancers [3, 4] and the increas-
ing risk is parallel to an increases in tobacco use [2].
Diet may also play a role in lung cancer etiology [4–6]. 
Among dietary factors, fruits, and vegetables are of much 
interest due to their potential anti- inflammatory and anti-
oxidant properties [7]. Carotenoids are found predominantly 
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Abstract
Carotenoids and retinol are considered biomarkers of fruits and vegetables  intake, 
and are of much interest because of their anti- inflammatory and antioxidant 
properties; however, there is inconsistent evidence regarding their protective 
effects against lung cancer. We conducted a meta- analysis of prospective studies 
of blood concentrations of carotenoids and retinol, and lung cancer risk. We 
identified relevant prospective studies published up to December 2014 by search-
ing the PubMed and several other databases. We calculated summary estimates 
of lung cancer risk for the highest compared with lowest carotenoid and retinol 
concentrations and dose–response meta- analyses using random effects models. 
We used fractional polynomial models to assess potential nonlinear relationships. 
Seventeen prospective studies (18 publications) including 3603 cases and 458,434 
participants were included in the meta- analysis. Blood concentrations of α- 
carotene, β- carotene, total carotenoids, and retinol were significantly inversely 
associated with lung cancer risk or mortality. The summary relative risk were 
0.66 (95% confidence interval [CI]: 0.55–0.80) per 5 μg/100 mL of α- carotene 
(studies [n] = 5), 0.84 (95% CI: 0.76–0.94) per 20 μg/100 mL of β- carotene 
(n = 9), 0.66 (95% CI: 0.54–0.81) per 100 μg/100 mL of total carotenoids 
(n = 4), and 0.81 (95% CI: 0.73–0.90) per 70 μg/100 mL of retinol (n = 8). 
In stratified analysis by sex, the significant inverse associations for β- carotene 
and retinol were observed only in men and not in women. Nonlinear associa-
tions were observed for β- carotene, β- cryptoxanthin, and lycopene, with stronger 
associations observed at lower concentrations. There were not enough data to 
conduct stratified analyses by smoking. In conclusion, higher blood concentra-
tions of several carotenoids and retinol are associated with reduced lung cancer 
risk. Further studies in never and former smokers are needed to rule out con-
founding by smoking. 
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in fruit and vegetables [8]. Blood carotenoids have been 
found to be highly correlated with fruits and vegetables 
intake in several studies, and are considered intake bio-
markers of fruit and vegetable [9–11].
According to World Cancer Research Fund/American 
Institute for Cancer Research (WCRF/AICR) Second Expert 
Report from 2007, foods containing carotenoids may pro-
tect against lung cancer (strength graded as probable) [12]. 
By contrast, two large randomized double- blind placebo- 
controlled trials, the alpha- tocopherol- β- carotene (ATBC) 
and the β- carotene and Retinol Efficacy Trial (CARET) 
showed an increased risk of lung cancer among high- risk 
people supplemented with high doses of β- carotene and/
or α- tocopherol [13–16].
A previous meta- analysis of prospective observational 
studies suggested a significant inverse association between 
lycopene and total carotenoids and lung cancer risk, how-
ever, the number of studies on blood concentrations of 
carotenoids was limited and there was no exploration of 
the shape of the dose–response relationship between carot-
enoids and lung cancer [6].
More recently, two additional prospective studies have 
been published, including 11,003 participants and 368 lung 
cancer cases [4, 17]. As part of the WCRF/AICR Continuous 
Update Project (CUP), we conducted an updated systematic 
review and meta- analysis of cohort studies with the aim to 
clarify the relationship of blood carotenoids and lung cancer 
risk. Retinol was also included in this review because of the 
conflicting results of randomized controlled trials [13–16].
Material and Methods
Search strategy
PubMed and several other databases, including, Embase, 
CABAbstracts, ISI Web of Science, BIOSIS, LILACS, 
Cochrane library, CINAHL, AMED, National Research 
Register, and In Process Medline, were searched for studies 
on blood concentrations of carotenoids and retinol up to 
January 2006 by several reviewers at the Johns Hopkins 
University for the WCRF/AICR Second Expert Report [12]. 
As all the relevant studies were identified by the PubMed 
search, we searched the PubMed database from January 
2006 up to December 2014. The specific search criteria 
and the review protocol can be found at http://www.wcrf.
org/sites/default/files/protocol_lung_ cancer.pdf. We also 
handsearched the reference lists of relevant articles, reviews, 
and meta- analyses identified in the search.
Study selection
Included were prospective cohort, nested case–control or 
case–cohorts studies that reported estimates of the relative 
risk (RR) (e.g., hazard ratio, risk ratio, or odds ratio) 
and 95% confidence intervals (CIs) of specific carotenoids, 
total carotenoids, or retinol in blood and lung cancer 
incidence or mortality. In case of multiple publications 
of the same study, the newest publication that included 
the largest number of cases was selected.
Data extraction
The following data were extracted from each publication: 
first author’s last name, publication year, country where 
the study was conducted, the study name, follow- up period, 
sample size, sex, age, number of cases, laboratory method 
for analysis, concentrations of carotenoids or retinol, and 
associated RRs and 95% CIs, and variables used in adjust-
ment in the analysis.
The search and data extraction of articles published up 
to December 2005 was conducted by several reviewers at 
the John Hopkins University during the systematic literature 
review for the WCRF/AICR Second Expert Report (available 
online: http://www.wcrf.org/sites/default/files/SLR_lung.pdf). 
The search and extraction from January 2006 and up to 
December 2014 was conducted by the CUP team at Imperial 
College London.
Statistical methods
Meta- analysis of the highest compared with the lowest 
blood concentrations of carotenoids and retinol, and the 
dose–response associations with lung cancer were conducted. 
Random effect models were used to calculate the summary 
RRs and 95% CIs to take into account heterogeneity across 
studies [18]. Heterogeneity was determined using Q and 
I² statistics [19], and was explored in stratified analyses 
when there were eight or more studies in the analysis.
When continuous risk estimates were not provided in 
the articles, dose–response associations and 95% CIs were 
derived from categorical data using generalized least- squares 
for trend estimation [20], which required the RRs and 
CIs associated to at least three categories of blood con-
centrations, number of cases, and noncases or person years 
of follow up per category.
The mean or median values per category were used if 
provided in the articles, or the midpoint was calculated 
for studies that only reported a range of blood concen-
trations of carotenoids and retinol by category. When the 
range of the highest or lowest category of carotenoid/
retinol concentrations was open- ended, its width was 
assumed to be the same as the adjacent category.
If only the total number of cases or person years was 
reported in the articles, and the exposure was categorized 
in quantiles, the distribution of cases or person years was 
calculated by dividing the total number of cases or person 
3© 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
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years by the number of quantiles. If the results were 
reported for men and women separately, they were com-
bined using a fixed effects meta- analysis before being 
pooled with other studies.
For studies that reported blood concentrations in μmol/L, 
the units were converted to μg/100 mL by dividing the 
concentration in μmol/L by 0.01863 for α- carotene, β- 
carotene, lycopene, and total carotenoids, and by 0.01809, 
0.01758, and 0.03491 for β- cryptoxanthin, lutein/zeaxan-
thin, and retinol, respectively [21].
Small- study effects, such as publication bias, were 
assessed using funnel plot and Egger’s test [22].
A potential nonlinear dose–response association between 
blood concentrations of carotenoids and retinol was assessed 
using fractional polynomial model [19] and the best- fitting 
second- order fractional polynomial regression model, 
defined as the one with the lowest deviance was deter-
mined. A two- tailed P < 0.05 was considered statistically 
significant.
In all analyses, the results of each paper with the most 
comprehensive adjustment for confounders were included. 
Stata version 12 software (StataCorp, College Station, TX) 
was used for all analyses.
Results
From 29,513 articles identified by the search of the 
Continuous Update Project, 28 articles (4 during the CUP 
and 24 during the SLR 2005), which met the inclusion 
criteria were included (flowchart of study selection—Fig. 1). 
Ten publications were excluded; five were duplicate pub-
lications and five publications did not provide enough data 
for analysis. In total, 18 publications (17 cohort studies) 
were included in the analyses [4, 13, 17, 23–37] (Table 1). 
Fourteen studies (3143 cases) reported on β- carotene [4, 17, 
23–34], seven studies on α- carotene (1205 cases) [4, 13, 
17, 23–26] and β- cryptoxanthin (1205 cases) [4, 17, 23–27], 
six studies on lycopene (1097 cases) [4, 17, 23–26], lutein 
Figure 1. Flowchart of study selection.
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and zeaxanthin (927 cases) [4, 17, 23, 24, 26, 27], and 
five studies on total carotenoids (724 cases) [4, 23, 24, 
26, 29]. Twelve studies (3192 cases) were on retinol [4, 
23–28, 31, 34–37]. Nine publications were among men 
only [13, 26–31, 33, 35] and nine publications were in 
both men and women [4, 17, 23–25, 32, 34, 36, 37]. Eight 
studies were from United States, four studies from Europe, 
four studies from Asia, and one study from Australia 
(Table 1).
Blood α- carotene
Five studies (1066 cases) were included in the dose–response 
meta- analysis [4, 17, 24–26]. A significant inverse associa-
tion was observed (Table 2). The summary RR for an 
increment of 5 μg/100 mL was 0.66 (95% CI: 0.55–0.80) 
(Fig. 2A). There was no evidence of heterogeneity (I² = 0%, 
Pheterogeneity = 0.69) or of publication or small- study bias 
(P value Egger’s test = 0.64). The overall RR for the 
highest versus lowest analysis was 0.70 (95% CI: 0.48–1.01, 
I² = 61%, Pheterogeneity = 0.02) in seven studies (Fig. S1A). 
Only three studies could be included in nonlinear meta- 
analysis and no evidence of nonlinearity was observed, 
Pnonlinearity = 0.11 (Fig. 2B).
Blood β- carotene
Nine studies (2958 cases) were included in the dose–
response meta- analysis [4, 17, 24–30]. A significant inverse 
association was observed (Table 2). The summary RR for 
an increase of 20 μg/100 mL was 0.84 (95% CI: 0.76–0.94) 
(Fig. 2C). There was moderate heterogeneity (I² = 40%, 
Pheterogeneity = 0.10) and no evidence of publication or 
small- study bias (P value Egger’s test = 0.28). An inverse 
association was observed in the highest versus lowest 
analysis (RR: 0.71; 95% CI: 0.56–0.91, I² = 55%, 
Pheterogeneity = 0.01) in 14 studies (Fig. S1B).
There was some evidence of a nonlinear dose–response 
of lung cancer and blood concentrations of β- carotene 
(Pnonlinearity = 0.05, n = 6), with the curve showing a 
slightly steeper slope in the low range of β- carotene con-
centrations (Fig. 2D), however, there was clear evidence 
of an inverse dose–response relationship across the range 
of β- carotene concentrations.
Blood β- cryptoxanthin
Six studies (1174 cases) were included in the dose–response 
meta- analysis [4, 17, 24–27]. A statistically nonsignificant, 
inverse association was observed (RR for an increase of 
10 μg/100 mL: 0.80; 95% CI: 0.57–1.12) (Table 2, Fig. 3A). 
There was high heterogeneity (I² = 77%, Pheterogeneity = 
0.001). There was no evidence of publication bias with 
Egger’s test (P = 0.23). Similarly, a nonsignificant inverse 
association was observed in the highest versus lowest analysis 
(RR: 0.72; 95% CI: 0.45–1.14, I² = 69%, Pheterogeneity = 
0.004) in seven studies (Fig. S2A).
Although, the test for nonlinearity was significant 
(Pnonlinearity = 0.03, n = 4) and there was a slightly stronger 
association at lower blood concentrations of β- 
cryptoxanthin, the association was nearly linear from 
5 μg/mL and above (Fig. 3B).
Blood lycopene
Five studies (1066 cases) were included in the dose–response 
meta- analysis [4, 17, 24–26]. A borderline significant inverse 
association was observed (RR for an increment of 
10 μg/100 mL: 0.90; 95% CI: 0.82–1.00) (Table 2, Fig. 3C). 
There was evidence of moderate heterogeneity (I² = 36%, 
Pheterogeneity = 0.18) and publication bias (P value Egger’s 
test = 0). The overall RR for the high versus low analysis 
was 0.68 (95% CI: 0.54–0.87, I² = 0%, Pheterogeneity = 0.78) 
in six studies (Table 2, Fig. S2B).
There was some evidence of nonlinear dose–response 
of lung cancer and blood concentration of lycopene 
(Pnonlinearity = 0.01, n = 3) (Fig. 3D). The inverse dose–
response association appeared to be stronger at low 
blood concentrations of lycopene (approximately up to 
20 μg/100 mL) with a weaker association beyond this 
level.
Blood lutein and zeaxanthin
Five studies (896 cases) were included in the dose–response 
meta- analysis [4, 17, 24, 26, 27] and six studies (927 
cases) in the highest versus lowest analysis. No significant 
associations were observed. The summary RR for an 
increase of 40 μg/100 mL was 0.84 (95% CI: 0.66–1.07, 
I² = 44%, Pheterogeneity = 0.13) and the RR for the highest 
versus lowest analysis was 0.86 (95% CI: 0.67–1.11, 
I² = 0%, Pheterogeneity = 0.53) (Table 2, Figs. 4A and S3A).
No evidence of nonlinear association was observed 
(Pnonlinearity = 0.51, n = 3) (Fig. 4B), although there was 
some suggestion of a negative association at higher 
concentrations.
Blood total carotenoids
Four studies (693 cases) were included in the dose–response 
meta- analysis [4, 24, 26, 29]. The summary RR for an 
increase of 100 μg/100 mL was 0.66 (95% CI: 0.54–0.81, 
I² = 0%, Pheterogeneity = 0.43) (Fig. 5A). There was no 
evidence of publication bias with Egger’s test (P = 0.30) 
but the number of studies was small. The overall RR for 
the high versus low analysis was 0.64 (95% CI: 0.44–0.93, 
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Table 2. Summary of results.
Linear dose–response meta- analysis Studies (n) Cases (n) RR (95% CI) I² (%) Pheterogeneity
α- carotene (per 5 μg/100 mL) 5 1066 0.66 (0.55–0.80) 0 0.69
β- carotene (per 20 μg/100 mL) 9 2958 0.84 (0.76–0.94) 40 0.10
β- cryptoxanthin (per 10 μg/100 mL) 6 1174 0.80 (0.57–1.12) 77 0.001
Lycopene (per 10 μg/100 mL) 5 1066 0.90 (0.82–1.00) 36 0.18
Lutein and zeaxanthin (per 40 μg/100 mL) 5 896 0.84 (0.66–1.07) 44 0.13
Retinol (per 70 μg/100 mL) 8 2855 0.81 (0.73–0.90) 9 0.36
Total carotenoids (per 100 μg/100 mL) 4 693 0.66 (0.54–0.81) 0 0.43
Highest vs. lowest meta- analysis
 α- carotene 7 1436 0.70 (0.48–1.01) 61 0.02
 β- carotene 14 3405 0.71 (0.56–0.91) 55 0.007
 β- cryptoxanthin 7 1205 0.72 (0.45–1.14) 69 0.004
 Lycopene 6 1097 0.68 (0.54–0.87) 0 0.78
 Lutein and zeaxanthin 6 927 0.86 (0.67–1.11) 0 0.53
 Retinol 11 3145 0.72 (0.63–0.81) 0 0.91
 Total carotenoids 5 724 0.64 (0.44–0.93) 23 0.27
Subgroup analysis
Linear dose–response 
meta- analysis
β- carotene, per 20 μg/100 mL Retinol, per 70 μg/100 mL
Studies 
(n)
Cases  
(n) RR (95% CI) I² (%) Pheterogeneity
Studies 
(n)
Cases  
(n) RR (95% CI) I² (%) Pheterogeneity
All studies 9 2958 0.84 (0.76–0.94) 40 0.10 8 2855 0.81 (0.73–0.90) 9 0.36
Stratified by sex
Men 7 2466 0.80 (0.69–0.93) 63 0.01 7 2499 0.76 (0.64–0.90) 44 0.10
Women 3 221 0.69 (0.39–1.21) 7 0.34 3 221 1.01 (0.76–1.32) 0 0.50
Stratified by outcome
Incidence 6 2518 0.88 (0.79–0.98) 43 0.12
Mortality 3 438 0.74 (0.60–0.90) 0 0.44
Stratified by geographic location
USA 5 788 0.87 (0.78–0.97) 14 0.32 3 636 0.89 (0.71–1.12) 41 0.18
Europe
Asia 3 525 0.87 (0.44–1.72) 68 0.04 3 528 0.72 (0.60–0.87) 0 0.64
After exclusion of studies in high- risk populations
6 928 0.81 (0.71–0.92) 32 0.19 4 778 0.84 (0.67–1.03) 53 0.10
Subgroup analysis by blood fasting status Studies (n) Cases (n) RR (95% CI) I² (%) Pheterogeneity
α- Carotene (per 5 μg/100 mL)
Fasting 1 207 0.70 (0.53–0.94)
Not fasting 2 487 0.80 (0.54–1.20) 0 0.92
Not indicated 2 372 0.57 (0.43–0.77) 0 0.69
β- Carotene (per 20 μg/100 mL)
Fasting 3 1959 0.86 (0.64–1.15) 70 0.04
Not fasting 3 561 0.92 (0.83–1.01) 0 0.55
Not indicated 3 438 0.74 (0.60–0.90) 0 0.44
β- Cryptoxanthin (per 10 μg/100 mL)
Fasting 2 315 1.59 (0.46–5.55) 89.9 0.002
Not fasting 2 487 0.40 (0.12–1.34) 70 0.07
Not indicated 2 372 0.69 (0.55–0.87) 0 0.52
Lycopene (per 10 μg/100 mL)
Fasting 1 207 0.91 (0.80–1.03)
Not fasting 2 487 0.78 (0.39–1.57) 46.6 0.17
Not indicated 2 372 0.71 (0.39–1.30) 69.9 0.07
Lutein and zeaxanthin (per 40 μg/100 mL)
Fasting 2 315 0.96 (0.69–1.35) 41.1 0.19
Not fasting 1 209 1.06 (0.66–1.69)
Not indicated 2 372 0.65 (0.49–0.86) 0 0.87
(Continued)
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I² = 23%, Pheterogeneity = 0.27) in five studies (724 cases) 
(Fig. 5B). The nonlinear dose–response analysis was not 
conducted because of the small number of studies with 
the required data (n = 2).
Blood retinol
Eight studies (2855 cases) were included in the dose–
response meta- analysis [4, 24–28, 36, 37]. A significant 
Subgroup analysis by blood fasting status Studies (n) Cases (n) RR (95% CI) I² (%) Pheterogeneity
Retinol (per 70 μg/100 mL)
Fasting 3 1959 0.87 (0.72–1.04) 40.8 0.18
Not fasting 3 534 0.64 (0.47–0.87) 0 0.84
Not indicated 2 362 0.80 (0.65–0.98) 21.6 0.26
Total carotenoids (per 100 μg/100 mL)
Fasting 1 207 0.74 (0.56–0.98)
Not fasting 1 209 0.68 (0.33–1.40)
Not indicated 2 277 0.54 (0.37–0.80) 6.6 0.30
RR, relative risk; 95% CI, 95% confidence interval.
Table 2. (Continued)
Figure 2. Blood concentration of α- carotene (A: dose-response analysis; B: nonlinear analysis) and β- carotene (C: dose-response analysis; D: nonlinear 
analysis), and lung cancer risk (dose–response and nonlinear analysis). RR, relative risk; 95% CI, 95% confidence interval. Summary RR calculated by 
using a random- effects model. Ito, 2005 (a) is JACC study.
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inverse association was observed. The summary RR 
for an increase of 70 μg/100 mL was 0.81 (95% CI: 
0.73–0.90, I² = 9%, Pheterogeneity = 0.36) (Fig. 4C). 
There was evidence of no publication bias (P = 0.67). 
The overall RR in high versus low analysis was 0.72 
(95% CI: 0.63–0.81, I² =0%, Pheterogeneity = 0.91) in 
11 studies (3145 cases) (Fig. S3B). There was some 
evidence of a nonlinear dose–response of lung cancer 
and serum retinol (Pnonlinearity = 0.02, n = 4), with 
wide CIs for higher exposures (Fig. 4D). No associa-
tion was observed in the MEC cohort [4] in which 
the retinol blood concentrations were higher than in 
the other studies.
Subgroup and sensitivity analyses
The subgroup analysis stratified by sex, cancer out-
come, and geographic location was conducted only 
for blood β- carotene and retinol because of small 
number of studies in the other blood carotenoids 
investigated. It was not possible to conduct stratified 
analyses by smoking status or histologic type of lung 
cancer because of lack of such data from the studies 
included.
The subgroup analysis stratified by blood fasting status 
was conducted and there was no strong evidence of dif-
ferent association as the CIs mostly overlap.
Blood β- carotene
When the analysis was repeated excluding the three studies 
in high- risk populations (high- risk miners, heavy smokers, 
or people exposed to asbestos) [25, 27, 28] the inverse 
dose–response association was slightly strengthened from 
0.84 (95% CI: 0.76–0.94) to 0.81 (95% CI: 0.71–0.92) 
(Fig. S4A). In stratified analysis by sex, the association 
was significant in men (RR: 0.80; 95% CI: 0.69–0.93, 
I² = 63%, Pheterogeneity = 0.01, n = 7, per 20 μg/100 mL) 
Figure 3. Blood concentration of β- cryptoxanthin (A: dose-response analysis; B: nonlinear analysis) and lycopene (C: dose-response analysis; D: 
nonlinear analysis), and lung cancer risk (dose–response and nonlinear analysis). RR, relative risk; 95% CI, 95% confidence interval. Summary RR 
calculated by using a random- effects model. Ito, 2005 (a) is JACC study.
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and inverse but not significant in women (RR: 0.69; 95% 
CI: 0.39–1.21, I² = 7%, Pheterogeneity = 0.34, n = 3, per 
20 μg/100 mL) for which statistical power was low 
(Table 2). The association was stronger in studies on lung 
cancer mortality (summary RR was 0.74; 95% CI: 0.60–0.90, 
I² = 0%, Pheterogeneity = 0.44, n = 3) than in studies on 
lung cancer incidence (summary RR was 0.88 (95% CI: 
0.79–0.98, I² = 43%, Pheterogeneity = 0.12, n = 6), but 
there was no strong evidence of a difference of associa-
tion as the CIs were overlapping (Table 2).
In terms of geographic location, the results were sig-
nificant only in studies conducted in the United States 
(five studies) but not in Asia (three studies) (Table 2).
Blood retinol
An inverse dose–response association was observed in men 
(2499 cases) and no association was observed in women 
(221 cases) (see Table 2). The summary RR’s per 70 μg/100 mL 
were 0.76 (95% CI: 0.64–0.90, n = 7) and 1.01 (95% CI: 
0.76–1.32, n = 3) in men and women, respectively.
The overall estimate was no longer statistically significant 
when the studies in high- risk populations were excluded [25, 
27, 28, 37] (RR: 0.84; 95% CI: 0.67–1.03, per 70 μg/100 mL). 
Only four studies remained in the analysis (Fig. S4B).
In stratified analysis by geographic location, the results 
were significant only in studies conducted in the Asia 
(three studies) but not in United States (three studies) 
(Table 2).
Discussion
In this meta- analysis, there was an inverse dose–response 
relationship of blood concentrations of α- carotene,  β- carotene, 
and total carotenoids, and lung cancer risk. An inverse asso-
ciation with blood concentrations of retinol was also observed. 
Figure 4. Blood concentration of lutein and zeaxanthin (A: dose-response analysis; B: nonlinear analysis) and retinol (C: dose-response analysis; D: 
nonlinear analysis), and lung cancer risk (dose–response and nonlinear analysis). RR, relative risk; 95% CI, 95% confidence interval. Summary RR 
calculated by using a random- effects model. Ito, 2005 (a) is JACC study.
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Subjects with the highest blood concentrations of total carot-
enoids and retinol had 19% and 34% lower RR of lung 
cancer when compared to those with the lowest blood con-
centrations, respectively. There was little evidence of hetero-
geneity in these analyses. Apart from the analysis of lycopene, 
there was no evidence of publication bias with the statistical 
tests used; however, the number of studies was limited.
To our knowledge, this is the first meta- analysis to 
examine a potential nonlinear association between blood 
concentrations of carotenoids and retinol, and lung cancer 
risk. The nonlinear dose–response analyses suggested inverse 
associations for all carotenoids, and in general, there was 
a stronger dose–response relationship in the lowest range 
of carotenoid and retinol concentrations than at the highest 
range. Nonlinearity was most pronounced for lycopene 
and retinol, for which there was a flattening of the dose–
response curve at the highest concentrations, while for 
most of the remaining carotenoids associations were slightly 
stronger at lowest compared to highest concentrations, but 
there was a clear inverse dose–response relationship with 
further reductions in risk with increasing carotenoid con-
centrations. These findings suggests that it might be most 
important to avoid low blood concentrations of lycopene 
and retinol, and that there is little further benefit in people 
with highest blood concentrations, while for alpha- carotene, 
beta- carotene, and beta- cryptoxanthin there might be further 
reductions in risk with increasing blood concentrations.
This study has several limitations which should be con-
sidered when interpreting the results. Smoking tends to be 
associated with lower intakes of fruit and vegetables, high 
intakes of fat and higher consumption of alcohol [38] and 
smokers have lower blood concentrations of some of carot-
enoids [39–41]. Therefore, it is possible that the observed 
inverse associations could have been due to residual 
confounding by cigarette smoking. With the exception of 
one study that only adjusted for age [31], all the studies 
included in our analysis were adjusted at least for smoking 
status, but there was not enough data to conduct subgroup 
analysis by smoking status. In the only study that showed 
separate results in smokers and never/former smokers [17], 
an inverse association with lung cancer mortality was observed 
for α- carotene and β- cryptoxanthin only in current smokers 
but not in never/former smokers, however, in a previous 
meta- analysis of fruit and vegetable intakes (some of which 
are high in carotenoids) and lung cancer risk, we found similar 
summary RRs among never smokers as compared to current 
or former smokers [42], although power was more limited 
among never smokers as the number of cases was modest.
Given the lack of data stratified by smoking status, 
further studies are needed in never smokers to rule out 
the potential confounding by smoking. Residual confound-
ing by other factors potentially related to the blood levels 
of the biomarkers investigated and to lung cancer is also 
a possibility. When the studies in high- risk populations—
high- risk miners, heavy smokers or people exposed to 
asbestos—were excluded from the meta- analysis in sen-
sitivity analysis, the inverse association with β- carotene 
[25, 27, 28] was slightly strengthened from 16% to 19% 
and the inverse association with retinol [25, 27, 28, 37] 
was no longer statistically significant.
Although there was a large number of studies that could 
be included in the dose–response analyses of β- carotene 
(n = 9) and retinol (n = 8), fewer studies reported on 
the other carotenoids (n = 4–6). The inverse associations 
were observed in men but not in women, and whether 
this is due to residual confounding, low number of cases 
in the analyses in women or gender differences is unclear 
and needs further study.
Figure 5. Blood concentration of total carotenoids (A: dose-response analysis; B: high vs low analysis) and lung cancer risk (dose–response and high 
vs. low analysis). RR, relative risk; 95% CI, 95% confidence interval. Summary RR calculated by using a random- effects model. Ito, 2005 (a) is JACC 
study and Ito, 2005 (b) is Japan, Hokkaido study.
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Furthermore, blood concentrations of carotenoids and 
retinol may not only reflect dietary intake, but can be 
influenced by the lipid content of the diet, metabolism 
and absorption, and genetic variability [7, 39, 40]. As 
carotenoids and retinol are fat- soluble, the lipid content 
of the diet increases the absorption. Some carotenoids 
including α and β- carotene, and β- cryptoxanthin can be 
partially metabolized to retinol, particularly in people with 
depleted vitamin A concentrations [40]. The absorption 
and hence the bioavailability of carotenoids can be modu-
lated by the fat content of the diet, competition with 
other carotenoids, degree of colon fermentation, and hor-
monal factors [40].
The results of this meta- analysis provide further sup-
port that high blood concentrations of carotenoids and 
retinol, as biomarkers of fruits and vegetable intake, are 
associated with reduced lung cancer risk. Carotenoids are 
found in many different types of fruit and vegetables, 
and it has been shown in epidemiological studies that 
dietary intakes of green and raw vegetables, carrots and 
broccoli are correlated with blood concentrations of α- 
carotene, β- carotene, and lutein/zeaxanthin [43], and fruits 
and root vegetables, carrots and tomato products are good 
predictors of β- cryptoxanthin, α- carotene and lycopene 
in plasma [44].
In contrast to the results of many observational studies 
and the current meta- analysis, two large randomized con-
trolled trials (RCT’s), the ATBC and CARET, showed an 
increased risk of lung cancer with high- dose supplemental 
β- carotene among smokers [14–16]. The increased risk 
at high doses may be related to the prooxidant activity 
of β- carotene when administered as a supplement in high 
doses (5–10 times greater than normal dietary intake) to 
heavy smokers [6, 45, 46]. In addition, it is possible that 
the difference in results between the RCTs and the obser-
vational studies may be because high blood concentrations 
of carotenoids and retinol simply may be markers of a 
high fruit and vegetable intake, but may not themselves 
be the constituent(s) responsible for the beneficial effect. 
Fruits and vegetables are not only good sources of carot-
enoids but also contain many other vitamins, minerals, 
fiber, antioxidants, and numerous phytochemicals [45] 
that could have a potential protective effect against lung 
cancer, and it is possible that a number of constituents 
may act synergistically [47].
Strength of this meta- analysis is the inclusion of pro-
spective cohort studies which avoids potential recall biases 
and that are less prone to selection biases than case–control 
studies. Some analyses included a large number of cases 
and had statistical power to detect relatively small associa-
tions but for some micronutrients the power may have 
been insufficient. Most studies, as mentioned previously, 
were adjusted for main confounders including smoking 
status, intensity, duration of smoking, and other smoking 
variables. Most of the studies measured the carotenoids 
and retinol blood concentrations using high- performance 
liquid chromatography (HPLC). The cancer outcome in 
the included studies was identified through cancer regis-
tries, death certificates and hospital records, and loss to 
follow- up was very low.
In conclusion, higher blood concentrations of total 
carotenoids, α- carotene, β- carotene, lycopene, and retinol 
were inversely associated with lung cancer risk. However, 
because of the lack of data in never smokers, further 
large scale studies stratified by smoking status are needed 
to rule out residual confounding by smoking.
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Supporting Information
Additional supporting information may be found in the 
online version of this article:
Figure S1. (A) α- carotene in blood and lung cancer, high 
versus low. (B) β- carotene in blood and lung cancer, 
high versus low.
Figure S2. (A) β- cryptoxanthin in blood and lung cancer, 
high versus low. (B) Lycopene in blood and lung cancer, 
high versus low.
Figure S3. (A) Lutein and zeaxanthin in blood and lung 
cancer, high versus low. (B) Retinol in blood and lung 
cancer, high versus low.
Figure S4. (A) β- carotene in blood and lung cancer, 
20 μg/100 mL. (B) Retinol in blood and lung cancer, 
70 μg/100 mL , after exclusion of studies in high risk 
populations.
